1. Academic Validation
  2. Novel Dual Mechanism GRT-X Agonist Acting on Kv7 Potassium Channel/Translocator Protein Receptor Prevents Motoneuron Degeneration Following Exposure to Mouse and Human Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Astrocyte-Conditioned Media

Novel Dual Mechanism GRT-X Agonist Acting on Kv7 Potassium Channel/Translocator Protein Receptor Prevents Motoneuron Degeneration Following Exposure to Mouse and Human Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Astrocyte-Conditioned Media

  • ACS Chem Neurosci. 2025 Aug 6;16(15):2887-2900. doi: 10.1021/acschemneuro.5c00197.
Vera M Masegosa 1 2 Elsa Fritz 3 Daniela Corvalan 3 Fabiola Rojas 3 Polett Garcés 3 Xavier Navarro 1 2 Petra Bloms-Funke 4 Brigitte van Zundert 3 5 6 Mireia Herrando-Grabulosa 1 2
Affiliations

Affiliations

  • 1 Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain.
  • 2 Centro de Investigación Biomédica en Red (CIBER), Instituto de Salud Carlos III, Madrid 28029, Spain.
  • 3 Institute of Biomedical Sciences (ICB), Faculty of Medicine & Faculty of Life Sciences, Universidad Andres Bello, Santiago 8370035, Chile.
  • 4 Grünenthal GmbH, Aachen 52099, Germany.
  • 5 Department of Neurology, University of Massachusetts Chan Medical School (UMMS), Worcester, Massachusetts 01655, United States.
  • 6 Millennium Nucleus of Neuroepigenetics and Plasticity (EpiNeuro), Santiago 8370035, Chile.
Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a continuous spectrum of aggressive neurodegenerative diseases affecting primarily motoneurons (MNs) and cortical frontotemporal neurons. Noncell autonomous mechanisms contribute to ALS/FTD, wherein astrocytes release toxic factor(s) detrimental to MNs. Because of the multifactorial nature of ALS, single-pathway-focused therapies have limited effectiveness in improving ALS. Therefore, novel combinatorial therapies are currently being pursued. Here, we evaluated whether the simultaneous activation of two complementary targets, the voltage-gated potassium channels 7.2/3 (Kv7.2/3) and the mitochondrial translocator protein (TSPO), by a novel synthesized compound (GRT-X) is an effective neuroprotective treatment in ALS in vitro models. We exposed primary rat ventral spinal cord neuronal cultures and rat spinal cord organotypic cultures to astrocyte-conditioned medium derived from primary mouse ALS astrocytes expressing mutant human SOD1 (SOD1G93A-ACM) or from human-induced pluripotent stem cell (iPSC)-derived astrocytes carrying an ALS-causing mutation in SOD1 (SOD1D90A-ACM) or an ALS/FTD-causing mutation in TDP-43 (TDP43A90 V-ACM). We report that the diverse human and mouse ALS/FTD-ACMs compromise the MN viability. Remarkably, GRT-X led to consistent protection of MNs. Moreover, ALS/FTD-ACM increases oxidative stress levels, which are prevented with GRT-X treatment. Together, we show that the complementary activation of TSPO and Kv7.2/3 may offer a novel therapeutic strategy for ALS/FTD due to its capacity to protect MNs from noncell-autonomous toxicity induced by diseased astrocytes.

Keywords

GRT-X; amyotrophic lateral sclerosis; astrocyte conditioned medium; frontotemporal dementia; motoneuron death; oxidative and excitotoxity stress.

Figures
Products